The role of triglyceride lipases in cancer associated cachexia

Trends in Molecular Medicine

Volumn 19, Issue 5, 2013, Pages 292-301

  Das, Suman K ^a   Hoefler, Gerald ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; GLYCOPROTEIN; IBROLIPIM; INTERLEUKIN 6; PRONALRESTAT; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; ANOREXIA; CACHEXIA; CANCER MORTALITY; HUMAN; HYDROLYSIS; HYPERLIPIDEMIA; LIPID METABOLISM; LIPOTOXICITY; NEOPLASM; NONHUMAN; REVIEW;

ANIMALS; CACHEXIA; HUMANS; LIPASE; LIPID METABOLISM; NEOPLASMS;

EID: 84877134318     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.02.006     Document Type: Review

References (109)

1. Dewys W.D., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 1980, 69:491-497.
2. Dewys W.D. Weight-loss and nutritional abnormalities in cancer-patients - incidence, severity and significance. Clin. Oncol. 1986, 5:251-261.
3. Blum D., Strasser F. Cachexia assessment tools. Curr. Opin. Support. Palliat. Care 2011, 5:350-355.
4. Fearon K.C.H., et al. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16:153-166.
5. Tisdale M.J. Mechanisms of cancer cachexia. Physiol. Rev. 2009, 89:381-410.
6. Richards C.H., et al. The relationships between body composition and the systemic inflammatory response in patients with primary operable colorectal cancer. PLoS ONE 2012, 7:e41883.
7. Evans W.K., et al. Limited impact of total parenteral nutrition on nutritional status during treatment for small cell lung cancer. Cancer Res. 1985, 45:3347-3353.
8. Kardinal C.G., et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990, 65:2657-2662.
9. Ovesen L., et al. Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. J. Clin. Oncol. 1993, 11:2043-2049.
10. Deans C., Wigmore S.J. Systemic inflammation, cachexia and prognosis in patients with cancer. Curr. Opin. Clin. Nutr. Metab. Care 2005, 8:265-269.
11. Fearon K.C., Moses A.G. Cancer cachexia. Int. J. Cardiol. 2002, 85:73-81.
12. Fearon K., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011, 12:489-495.
13. Argiles J.M., et al. The cachexia score (CASCO): a new tool for staging cachectic cancer patients. J. Cachexia Sarcopenia Muscle 2011, 2:87-93.
14. Fearon K.C. The Sir David Cuthbertson Medal Lecture 1991. The mechanisms and treatment of weight loss in cancer. Proc. Nutr. Soc. 1992, 51:251-265.
15. Agustsson T., et al. Adipose tissue volume is decreased in recently diagnosed cancer patients with cachexia. Nutrition 2012, 28:851-855.
16. Fouladiun M., et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care - correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005, 103:2189-2198.
17. Chung T.H., et al. YC-1 rescues cancer cachexia by affecting lipolysis and adipogenesis. Int. J. Cancer 2011, 129:2274-2283.
18. Das S.K., et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011, 333:233-238.
19. Fearon K.C. Cancer cachexia and fat-muscle physiology. N. Engl. J. Med. 2011, 365:565-567.
20. Argiles J.M., et al. Mechanisms to explain wasting of muscle and fat in cancer cachexia. Curr. Opin. Support. Palliat. Care 2007, 1:293-298.
21. Ryden M., et al. Lipolysis - not inflammation, cell death, or lipogenesis - is involved in adipose tissue loss in cancer cachexia. Cancer 2008, 113:1695-1704.
22. Trew J.A., Begg R.W. In vitro incorporation of acetate-1-C14 into adipose tissue from normal and tumor-bearing rats. Cancer Res. 1959, 19:1014-1019.
23. Lanza-Jacoby S., et al. Sequential changes in the activities of lipoprotein lipase and lipogenic enzymes during tumor growth in rats. Cancer Res. 1984, 44:5062-5067.
24. Mulligan H.D., Tisdale M.J. Lipogenesis in tumour and host tissues in mice bearing colonic adenocarcinomas. Br. J. Cancer 1991, 63:719-722.
25. Thompson M.P., et al. Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients. Biochim. Biophys. Acta 1993, 1180:236-242.
26. Notarnicola M., et al. Low levels of lipogenic enzymes in peritumoral adipose tissue of colorectal cancer patients. Lipids 2012, 47:59-63.
27. Shaw J.H., Wolfe R.R. Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann. Surg. 1987, 205:368-376.
28. Drott C., et al. Cardiovascular and metabolic response to adrenaline infusion in weight-losing patients with and without cancer. Clin. Physiol. 1989, 9:427-439.
29. Legaspi A., et al. Whole body lipid and energy metabolism in the cancer patient. Metabolism 1987, 36:958-963.
30. Gercel-Taylor C., et al. Aberrations in normal systemic lipid metabolism in ovarian cancer patients. Gynecol. Oncol. 1996, 60:35-41.
31. Dahlman I., et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br. J. Cancer 2010, 102:1541-1548.
32. Stephens N.A., et al. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia Sarcopenia Muscle 2011, 2:111-117.
33. Bing C., et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br. J. Cancer 2006, 95:1028-1037.
34. Obeid O.A., Emery P.W. Lipid metabolism in cachectic tumor-bearing rats at different stages of tumor growth. Nutr. Cancer 1993, 19:87-98.
35. Nomura K., et al. Plasma interleukin-6 is not a mediator of changes in lipoprotein lipase activity in cancer patients. Hepatogastroenterology 1997, 44:1519-1526.
36. Briddon S., et al. Changes in activity of lipoprotein lipase, plasma free fatty acids and triglycerides with weight loss in a cachexia model. Cancer Lett. 1991, 57:49-53.
37. Marshall M.K., et al. Leukemia inhibitory factor induces changes in lipid metabolism in cultured adipocytes. Endocrinology 1994, 135:141-147.
38. Berg M., et al. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 1994, 6:425-432.
39. Nara-Ashizawa N., et al. Lipolytic and lipoprotein lipase (LPL)-inhibiting activities produced by a human lung cancer cell line responsible for cachexia induction. Anticancer Res. 2001, 21:3381-3387.
40. Nomura K., et al. Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate. Surg. Today 1996, 26:89-94.
41. Kawamura I., et al. Effect of lipoprotein lipase activators bezafibrate and NO-1886, on B16 melanoma-induced cachexia in mice. Anticancer Res. 1999, 19:4099-4103.
42. Kawamura I., et al. Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor. Anticancer Res. 1999, 19:341-348.
43. Vaughan M., et al. Hormone-sensitive lipase and monoglyceride lipase activities in adipose tissue. J. Biol. Chem. 1964, 239:401-409.
44. Lass A., et al. Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Prog. Lipid Res. 2011, 50:14-27.
45. Zechner R., et al. FAT SIGNALS - lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012, 15:279-291.
46. Olsson H., et al. Phosphorylation of the basal site of hormone-sensitive lipase by glycogen synthase kinase-4. FEBS Lett. 1986, 209:175-180.
47. Krintel C., et al. Ser649 and Ser650 are the major determinants of protein kinase A-mediated activation of human hormone-sensitive lipase against lipid substrates. PLoS ONE 2008, 3:e3756.
48. Garton A.J., et al. Phosphorylation of bovine hormone-sensitive lipase by the AMP-activated protein kinase. A possible antilipolytic mechanism. Eur. J. Biochem. 1989, 179:249-254.
49. Miyoshi H., et al. Control of adipose triglyceride lipase action by serine 517 of perilipin A globally regulates protein kinase A-stimulated lipolysis in adipocytes. J. Biol. Chem. 2007, 282:996-1002.
50. Wang H., et al. Activation of hormone-sensitive lipase requires two steps, protein phosphorylation and binding to the PAT-1 domain of lipid droplet coat proteins. J. Biol. Chem. 2009, 284:32116-32125.
51. Cao D.X., et al. Role of β1-adrenoceptor in increased lipolysis in cancer cachexia. Cancer Sci. 2010, 101:1639-1645.
52. Agustsson T., et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007, 67:5531-5537.
53. Villena J.A., et al. Desnutrin, an adipocyte gene encoding a novel patatin domain-containing protein, is induced by fasting and glucocorticoids: ectopic expression of desnutrin increases triglyceride hydrolysis. J. Biol. Chem. 2004, 279:47066-47075.
54. Zimmermann R., et al. Fat mobilization in adipose tissue is promoted by adipose triglyceride lipase. Science 2004, 306:1383-1386.
55. Jenkins C.M., et al. Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities. J. Biol. Chem. 2004, 279:48968-48975.
56. Yang X., et al. Relative contribution of adipose triglyceride lipase and hormone-sensitive lipase to tumor necrosis factor-α (TNF-α)-induced lipolysis in adipocytes. J. Biol. Chem. 2011, 286:40477-40485.
57. Kershaw E.E., et al. PPARγ regulates adipose triglyceride lipase in adipocytes in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1736-E1745.
58. Lass A., et al. Adipose triglyceride lipase-mediated lipolysis of cellular fat stores is activated by CGI-58 and defective in Chanarin-Dorfman syndrome. Cell Metab. 2006, 3:309-319.
59. Yang X., et al. The G(0)/G(1) switch gene 2 regulates adipose lipolysis through association with adipose triglyceride lipase. Cell Metab. 2010, 11:194-205.
60. Schoiswohl G., et al. Adipose triglyceride lipase plays a key role in the supply of the working muscle with fatty acids. J. Lipid Res. 2010, 51:490-499.
61. Badin P.M., et al. Altered skeletal muscle lipase expression and activity contribute to insulin resistance in humans. Diabetes 2011, 60:1734-1742.
62. Olivecrona G. The crucial role of ATGL for energy supply of muscles. J. Lipid Res. 2010, 51:449-450.
63. Kawakami M., Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J. Exp. Med. 1981, 154:631-639.
64. Kawakami M., et al. Lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced mediator from exudate cells. Proc. Natl. Acad. Sci. U.S.A. 1982, 79:912-916.
65. Beutler B., Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986, 320:584-588.
66. Karayiannakis A.J., et al. Serum levels of tumor necrosis factor-α and nutritional status in pancreatic cancer patients. Anticancer Res. 2001, 21:1355-1358.
67. Kawakami M., et al. Human recombinant TNF suppresses lipoprotein lipase activity and stimulates lipolysis in 3T3-L1 cells. J. Biochem. 1987, 101:331-338.
68. Li L., et al. The adipose triglyceride lipase, adiponectin and visfatin are downregulated by tumor necrosis factor-α (TNF-α) in vivo. Cytokine 2009, 45:12-19.
69. Kim J.Y., et al. The adipose tissue triglyceride lipase ATGL/PNPLA2 is downregulated by insulin and TNF-α in 3T3-L1 adipocytes and is a target for transactivation by PPARγ. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E115-E127.
70. Kralisch S., et al. Isoproterenol, TNFα, and insulin downregulate adipose triglyceride lipase in 3T3-L1 adipocytes. Mol. Cell. Endocrinol. 2005, 240:43-49.
71. Bezaire V., et al. Chronic TNFα and cAMP pre-treatment of human adipocytes alter HSL, ATGL and perilipin to regulate basal and stimulated lipolysis. FEBS Lett. 2009, 583:3045-3049.
72. Souza S.C., et al. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor α to increase lipolysis in 3T3-L1 adipocytes. J. Biol. Chem. 1998, 273:24665-24669.
73. Sherry B.A., et al. Anticachectin/tumor necrosis factor-α antibodies attenuate development of cachexia in tumor models. FASEB J. 1989, 3:1956-1962.
74. Lopez-Soriano J., et al. Lipid metabolism in tumour-bearing mice: studies with knockout mice for tumour necrosis factor receptor 1 protein. Mol. Cell. Endocrinol. 1997, 132:93-99.
75. Mahony S.M., et al. Comparison of weight loss induced by recombinant tumour necrosis factor with that produced by a cachexia-inducing tumour. Br. J. Cancer 1988, 57:385-389.
76. Ji C., et al. IL-6 induces lipolysis and mitochondrial dysfunction, but does not affect insulin-mediated glucose transport in 3T3-L1 adipocytes. J. Bioenerg. Biomembr. 2011, 43:367-375.
77. Yang Y., et al. Interleukin-6 stimulates lipolysis in porcine adipocytes. Endocrine 2008, 33:261-269.
78. Strassmann G., et al. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 1992, 89:1681-1684.
79. Tsoli M., et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 2012, 72:4372-4382.
80. Staal-van den Brekel A.J., et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J. Clin. Oncol. 1995, 13:2600-2605.
81. Maltoni M., et al. Serum levels of tumour necrosis factor α and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support. Care Cancer 1997, 5:130-135.
82. Soda K., et al. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int. J. Cancer 1995, 62:332-336.
83. Inadera H., et al. Molecular analysis of lipid-depleting factor in a colon-26-inoculated cancer cachexia model. Int. J. Cancer 2002, 101:37-45.
84. McDevitt T.M., et al. Purification and characterization of a lipid-mobilizing factor associated with cachexia-inducing tumors in mice and humans. Cancer Res. 1995, 55:1458-1463.
85. Todorov P.T., et al. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res. 1998, 58:2353-2358.
86. Hirai K., et al. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res. 1998, 58:2359-2365.
87. Bing C., et al. Zinc-α2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:2500-2505.
88. Rolli V., et al. Lipolysis is altered in MHC class I zinc-α(2)-glycoprotein deficient mice. FEBS Lett. 2007, 581:394-400.
89. Russell L., Forsdyke D.R. A human putative lymphocyte G0/G1 switch gene containing a CpG-rich island encodes a small basic protein with the potential to be phosphorylated. DNA Cell Biol. 1991, 10:581-591.
90. Welch C., et al. Identification of a protein, G0S2, that lacks Bcl-2 homology domains and interacts with and antagonizes Bcl-2. Cancer Res. 2009, 69:6782-6789.
91. Yamada T., et al. The cytosolic protein G0S2 maintains quiescence in hematopoietic stem cells. PLoS ONE 2012, 7:e38280.
92. Zandbergen F., et al. The G0/G1 switch gene 2 is a novel PPAR target gene. Biochem. J. 2005, 392:313-324.
93. Schweiger M., et al. G0/G1 switch gene-2 regulates human adipocyte lipolysis by affecting activity and localization of adipose triglyceride lipase. J. Lipid Res. 2012, 53:2307-2317.
94. Sauer L.A., et al. Dietary factors and growth and metabolism in experimental tumors. J. Nutr. Biochem. 2007, 18:637-649.
95. Sauer L.A., Dauchy R.T. Blood nutrient concentrations and tumor growth in vivo in rats: relationships during the onset of an acute fast. Cancer Res. 1987, 47:1065-1068.
96. Sauer L.A., et al. Stimulation of tumor growth in adult rats in vivo during an acute fast. Cancer Res. 1986, 46:3469-3475.
97. Sauer L.A., Dauchy R.T. Stimulation of tumor growth in adult rats in vivo during acute streptozotocin-induced diabetes. Cancer Res. 1987, 47:1756-1761.
98. Mulligan H.D., Tisdale M.J. Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. Br. J. Cancer 1991, 64:1035-1038.
99. Tisdale M.J., Beck S.A. Inhibition of tumour-induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem. Pharmacol. 1991, 41:103-107.
100. van Herpen N.A., Schrauwen-Hinderling V.B. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol. Behav. 2008, 94:231-241.
101. Summers S.A. Ceramides in insulin resistance and lipotoxicity. Prog. Lipid Res. 2006, 45:42-72.
102. Galic S., et al. Adipose tissue as an endocrine organ. Mol. Cell. Endocrinol. 2010, 316:129-139.
103. Fruhbeck G., et al. The adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E827-E847.
104. Ahima R.S. Adipose tissue as an endocrine organ. Obesity (Silver Spring) 2006, 14(Suppl. 5):242S-249S.
105. Pedersen B.K. Edward F. Adolph distinguished lecture: muscle as an endocrine organ: IL-6 and other myokines. J. Appl. Physiol. 2009, 107:1006-1014.
106. Lancaster G.I., Febbraio M.A. Skeletal muscle: not simply an organ for locomotion and energy storage. J. Physiol. 2009, 587:509-510.
107. Febbraio M.A., Pedersen B.K. Contraction-induced myokine production and release: is skeletal muscle an endocrine organ?. Exerc. Sport Sci. Rev. 2005, 33:114-119.
108. Zhou Q., et al. Evidence for adipose-muscle cross talk: opposing regulation of muscle proteolysis by adiponectin and fatty acids. Endocrinology 2007, 148:5696-5705.
109. Pedersen B.K., et al. Muscle-derived interleukin-6: lipolytic, anti-inflammatory and immune regulatory effects. Exerc. Sport Sci. Rev. 2003, 446:9-16.